EA201992594A1 - COMBINED THERAPIES FOR TREATMENT OF CANCER - Google Patents

COMBINED THERAPIES FOR TREATMENT OF CANCER

Info

Publication number
EA201992594A1
EA201992594A1 EA201992594A EA201992594A EA201992594A1 EA 201992594 A1 EA201992594 A1 EA 201992594A1 EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A1 EA201992594 A1 EA 201992594A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
combined therapies
agent
signaling pathway
Prior art date
Application number
EA201992594A
Other languages
Russian (ru)
Inventor
Дмитри Бобилев
Брюс Дезьюб
Пэн Сунь
Эндрю Р. Фергюсон
Original Assignee
Тесаро, Инк.
Мерк Шарп и Доум Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк., Мерк Шарп и Доум Б.В. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/031876 external-priority patent/WO2018208968A1/en
Publication of EA201992594A1 publication Critical patent/EA201992594A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предлагаются способы лечения рецидивирующего рака (рецидивирующих раков) путем применения комбинированной терапии, включающей средство, которое ингибирует активацию сигнального пути рецептора программируемой гибели клеток типа 1 (PD-1), и средство, которое ингибирует активацию сигнального пути поли[ADP-рибоза]полимеразы (PARP).The present invention provides methods of treating recurrent cancer (recurring cancers) by using combination therapy comprising an agent that inhibits activation of a programmed cell death receptor signaling pathway of type 1 (PD-1) and an agent that inhibits activation of a poly [ADP-ribose signaling pathway ] polymerase (PARP).

EA201992594A 2018-03-26 2018-05-09 COMBINED THERAPIES FOR TREATMENT OF CANCER EA201992594A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648327P 2018-03-26 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
EA201992594A1 true EA201992594A1 (en) 2020-03-20

Family

ID=69942862

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992594A EA201992594A1 (en) 2018-03-26 2018-05-09 COMBINED THERAPIES FOR TREATMENT OF CANCER

Country Status (1)

Country Link
EA (1) EA201992594A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Similar Documents

Publication Publication Date Title
MX2019013755A (en) Combination therapies for treating cancer.
MX2019013373A (en) Combination therapies for treating cancer.
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
EA201792191A1 (en) FGFR / PD-1 COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMOR
EA201992594A1 (en) COMBINED THERAPIES FOR TREATMENT OF CANCER
BR112018003985A2 (en) peptidomimetic macrocycles and their uses
NZ754865A (en) Combination therapy for the treatment of cancer
MX2022001075A (en) Ar+ breast cancer treatment methods.
MX2017015811A (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways.
MX2017011206A (en) Combination of a pd-1 antagonist and eribulin for treating cancer.
PH12019502259A1 (en) Glucocorticoid receptor modulators to treat cervical cancer
CR20220353A (en) Compounds and methods for the targeted degradation of androgen receptor
BR112017028530A2 (en) combination therapy for treatment of haematological cancers and solid tumors
MX2019012464A (en) Combination therapy with an anti-axl antibody-drug conjugate.
EA201990567A1 (en) COMBINED THERAPY WITH GLUTAMINASE INHIBITORS
EA202191556A1 (en) COMBINED THERAPY WITH RADIO IMMUNOCONJUGATES AND CONTROL POINT INHIBITORS
EA201892284A1 (en) COMBINATION OF ANTIBODY AGAINST CD20, SELECTIVE PI3-KINASE-DELTA INHIBITOR AND BTK INHIBITOR FOR TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
BR112022011998A2 (en) USES OF ANTI-TGFSS ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ZA201907225B (en) Treatment of her2 positive cancers
MX2019003994A (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer.
MX2019010149A (en) Inhibition of smarca2 for treatment of cancer.
MX2021004366A (en) Neurological disease treatment with zilucoplan.
MX2020008408A (en) Granzyme b directed imaging and therapy.
MX2023008849A (en) Combination therapy using a liv1-adc and a chemotherapeutic.
MX2022014180A (en) Methods, therapies and uses for treating cancer.